Skip to main content
Pherecydes Pharma logo

Pherecydes Pharma — Investor Relations & Filings

Ticker · ALPHE ISIN · FR0011651694 LEI · 894500LYT3UUN58X3I68 PA Professional, scientific and technical activities
Open in API
Filings indexed 146 across all filing types
Latest filing 2022-06-08 Regulatory Filings
Country FR France
Listing PA ALPHE

About Pherecydes Pharma

https://www.pherecydes-pharma.com/en/

Pherecydes Pharma is a clinical-stage biotechnology company specializing in the research and development of phage therapy to combat antibiotic-resistant bacterial infections. The company develops targeted treatments using bacteriophages, which are naturally occurring viruses that specifically infect and destroy bacteria. Its therapeutic approach focuses on providing personalized solutions for severe infections, particularly those caused by Staphylococcus aureus, Pseudomonas aeruginosa, and Escherichia coli. The company utilizes a proprietary phage bank and a diagnostic tool to determine the most effective phages for each patient's specific bacterial strain. In 2023, Pherecydes Pharma merged with Erytech to form Phaxiam Therapeutics, combining expertise to advance phage therapy as a mainstream anti-infective solution.

Recent filings

Filing Released Lang Actions
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 100% confidence The document is a press release dated June 8, 2022, announcing that Pherecydes Pharma will participate in and host a scientific symposium ('La phagothérapie en 2022 : expérience française') during the 23rd National Days of Infectiology (JNI). It details the speakers and topics, and includes standard 'About the Company' and 'Contacts' sections, concluding with a standard forward-looking statement disclaimer. This is a general corporate announcement regarding participation in an industry event, not a formal regulatory filing like a 10-K, an earnings release (ER), or a specific financial report (IR, AR). Since it is an announcement about company activity and communication strategy, it best fits the general 'Regulatory Filings' (RNS) category as a miscellaneous corporate communication, although it is not a formal regulatory filing in the strict sense. Given the options, RNS is the most appropriate fallback for a general press release announcing participation in an event.
2022-06-08 French
Inside Information / Other news releases
Report Publication Announcement Classification · 99% confidence The document is a press release dated June 8, 2022, announcing that Pherecydes Pharma will participate in a scientific symposium during the 23rd National Days of Infectiology (NDI) on June 15, 2022. It details the symposium's topic, speakers, and includes commentary from the Medical Director regarding antibiotic resistance and phage therapy studies. This is an announcement about a company event/activity, not a formal regulatory filing like a 10-K, an earnings release (ER), or a formal investor presentation (IP). It is best classified as a general announcement or news release. Since there is no specific category for 'Event Announcement' and it is not a standard regulatory filing, the most appropriate fallback category is 'Regulatory Filings' (RNS), which covers general regulatory announcements and miscellaneous filings.
2022-06-08 English
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 95% confidence The document is a press release dated May 30, 2022, announcing that Pherecydes Pharma obtained 'Autorisation d'Accès Compassionnel (AAC)' from the ANSM (French National Agency for the Safety of Medicines and Health Products) for its anti-Staphylococcus aureus phages. This announcement details a regulatory/access milestone that allows the company to generate initial revenue and discusses future plans for other phages. This type of announcement, focusing on a specific regulatory approval or access status that is not a standard periodic financial report (like 10-K or IR), fits best under the general 'Regulatory Filings' category (RNS) as it is a significant, non-financial, operational/regulatory update. It is too specific for 'CAP' (Financing) or 'ER' (Earnings Release). Since it is a formal announcement of a regulatory event, RNS is the most appropriate general regulatory category.
2022-05-30 French
Inside Information / Other news releases
Regulatory Filings Classification · 90% confidence The document is a press release dated May 30, 2022, announcing that Pherecydes Pharma obtained 'AAC Early Access Program approval' from the ANSM for its anti-*Staphylococcus aureus* phages. This announcement details a regulatory/access milestone related to a medical product, which is not a standard periodic financial report (like 10-K or IR) nor a standard earnings release (ER). It is an announcement concerning a specific regulatory/access development that impacts the company's operations and potential revenue generation. Since it is a specific announcement about regulatory/access status rather than a general regulatory filing (RNS) or a specific financial report, it best fits under the category of a general announcement or a specific regulatory/legal update. Given the options, it is a specific corporate announcement that doesn't fit the financial reporting codes (10-K, IR, ER, MRQ). It is not a Director's Dealing (DIRS), Dividend (DIV), or Capital Change (CAP). It is most closely related to a significant operational/regulatory event. Since there is no specific code for 'Regulatory Approval Announcement', and it is not a standard financial report, the most appropriate fallback category for a significant, non-standard corporate announcement is 'Regulatory Filings' (RNS), although 'LTR' (Legal Proceedings Report) is sometimes used for regulatory actions, this is an approval, not a proceeding. Given the context of corporate news releases that don't fit other specific financial categories, RNS is the best fit as a general regulatory announcement.
2022-05-30 English
Informations privilégiées / Autres communiqués
AGM Information Classification · 98% confidence The document explicitly discusses the results and decisions made during the 'assemblée générale mixte (AGM)' held on May 19, 2022. Key topics include the approval of governance evolution to a Board of Directors structure and the subsequent appointment of new executive roles (President CEO and Deputy CEO). This content directly relates to the proceedings and outcomes of the Annual General Meeting. Therefore, the most appropriate classification is AGM Information (AGM-R).
2022-05-23 French
Inside Information / Other news releases
AGM Information Classification · 99% confidence The document explicitly discusses the outcomes and decisions made during the 'Combined General Meeting (AGM)' held on May 19, 2022. Key elements include the approval of governance changes (adopting a Board of Directors), the appointment of new Chairman/CEO (Didier Hoch) and Deputy CEO (Thibaut du Fayet), and the results of shareholder votes on resolutions. This content directly relates to the proceedings and outcomes of the Annual General Meeting. Therefore, the most appropriate classification is AGM Information (AGM-R). Although it mentions voting results, the primary focus is the overall meeting outcome and governance evolution, making AGM-R stronger than DVA (Declaration of Voting Results & Voting Rights Announcements).
2022-05-23 English

Browse filings by year

3 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.